Research Reports

Q3 2025 consolidated revenue of $137 million, down 2.1% YoY (CFO).
Product revenue $94.1 million, flat YoY; system revenue $32.1 million (up from $31.7 million), consumables $62 million (vs $62.4 million) (CFO).
Service revenue $42.9 million (down from $45.9 million); customer support $29.3 million (down from $31 million) (CFO).
GAAP gross margin 41.0% (vs 44.8% YoY); non-GAAP gross margin 45.3% (vs 49.6% YoY) (CFO).
GAAP operating expenses $78.8 million (57.5% of revenue), down from $88.2 million (63.0% of revenue) YoY (CFO).
Non-GAAP operating expenses $62.0 million (45.3% of revenue), down from $69.6 million YoY (CFO).
GAAP net loss $55.6 million ($0.65/diluted share), including $33.9 million non-cash impairment on Ultimaker investment; non-GAAP net income $1.5 million ($0.02/diluted share) (CFO).
Adjusted EBITDA $5.0 million (vs $5.1 million YoY) (CFO).
Operating cash flow $6.9 million, vs use of $4.5 million in Q3 2024 (CFO).
Cash, equivalents, and short-term deposits $255 million, no debt (CFO).

FY2025 revenue reaffirmed: $550 million – $560 million (CFO).
FY2025 non-GAAP gross margin: 46.7% – 47.0% (CFO).
FY2025 non-GAAP operating margin: 1.5% – 2.0% (CFO).
FY2025 adjusted EPS: $0.13 – $0.16; adjusted EBITDA: $30 million – $32 million (CFO).
FY2025 operating cash flow expected to show year-over-year growth (CFO).

"Our disciplined approach to cost management enabled us to deliver solid operating cash flow generation and EPS in the third quarter." (CEO)
"The evolving trade and tariff landscape, while creating near-term complexity, ultimately reinforces the strategic value proposition of localized flexible manufacturing." (CEO)
"We are proud to be among the first dental additive companies to proactively remove TPO, a common but controversial toxic chemical, from all our dental resins." (CEO)
"The change versus the prior year period [in gross margin] was in large part due to the increase in tariff. When we initially discussed our expectations, the tariff rate had been set at 10%. However, subsequent to our comments, it was raised to 15%." (CFO)
"We ended the quarter with $255 million in cash, cash equivalents, and short-term deposits, $400,000 higher than at the end of the second quarter, with no debt." (CFO)

Topic: 毛利率趋势及2026年营收增长机会
Key points:
- Q3毛利率受关税、产品组合及去库存（库存减少）影响，已提价，预计Q4起毛利率改善并延续至2026年，但未给出具体改善幅度。
- 公司聚焦制造业，重点应用领域为航空航天与国防、牙科、医疗、工装、工业机械部件及消费电子部件；AI社交媒体公司及媒体公司已带来机会。
- 预计这些应用领域2026年将实现增长，已在硬件上看到显著增长。
Mgmt stance: 乐观（明确指向2026年增长，并强调在高端市场的领先地位）

Topic: 生产型应用销售周期及耗材收入展望
Key points:
- 同一批机会（航空航天等），销售周期长期（1-2年），但本季度首次看到销售周期“隧道尽头的光亮”，轻微改善。
- 举例：A.M. Craft 本季度购买两台F900，加上F900与F3300总数达10台；公司正认证亚利桑那、明尼苏达工厂为认证航空零件生产点，目标成为全球最大认证航空零件服务局。
- 耗材：全年耗材预计持平或稳定，因环境挑战但模型有韧性；未来随高端工业机器（F3300、H350等）销售增加，耗材消耗将逐步上升（高端机器消耗量可达原型机的10倍）。
Mgmt stance: 中性偏乐观（销售周期有改善信号，耗材短期稳定但长期看增）

Topic: 运营支出趋势及材料定价/毛利率
Key points:
- 非GAAP OpEx：Q3为6200万美元（去年同期6960万），预计Q4环比小幅下降。公司将继续严格管控OpEx并投资R&D及销售。
- 材料定价：高性能材料在航空航天等领域认证是壁垒而非成本；公司在材料方面通过收购和整合实现规模，长期将逐步降低材料价格以渗透更多应用。
Mgmt stance: 中性（OpEx持续收紧，材料定价有计划但未承诺立即变化）

Topic: 牙科机会规模及F3300大客户（AI社交媒体公司）后续潜力
Key points:
- 牙科：招募了前Affordable Care专家Chris Cabot；聚焦修复牙科，使用PolyJet和P3技术；已获美国两大供应商（Affordable Care和Glidewell）客户。
- F3300大客户（疑似Meta）：销售周期长，经认证和测试后胜出；客户从原型转向生产，同一机器可同时用于制造，优势在于上市速度；潜在增量需求巨大，但未透露具体采购计划。
Mgmt stance: 乐观（牙科有明确计划和领先技术；F3300客户验证了高端FDM能力，前景看好）